1. Home
  2. HWBK vs CABA Comparison

HWBK vs CABA Comparison

Compare HWBK & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HWBK

Hawthorn Bancshares Inc.

HOLD

Current Price

$34.46

Market Cap

231.4M

Sector

Finance

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.39

Market Cap

227.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HWBK
CABA
Founded
1865
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
231.4M
227.2M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
HWBK
CABA
Price
$34.46
$2.39
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$13.50
AVG Volume (30 Days)
11.3K
2.2M
Earning Date
01-21-2026
11-10-2025
Dividend Yield
2.19%
N/A
EPS Growth
259.86
N/A
EPS
3.19
N/A
Revenue
$77,904,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.43
N/A
Revenue Growth
45.83
N/A
52 Week Low
$25.21
$0.99
52 Week High
$36.49
$3.67

Technical Indicators

Market Signals
Indicator
HWBK
CABA
Relative Strength Index (RSI) 54.12 48.77
Support Level $33.85 $2.32
Resistance Level $36.25 $2.49
Average True Range (ATR) 0.99 0.14
MACD -0.01 -0.00
Stochastic Oscillator 29.80 18.42

Price Performance

Historical Comparison
HWBK
CABA

About HWBK Hawthorn Bancshares Inc.

Hawthorn Bancshares Inc is a financial holding company and along with its subsidiary, it conducts general banking and trust business, offering its customers checking and savings accounts, internet banking, certificates of deposit, trust services, brokerage services, and safety deposit boxes. The company also offers a range of lending services, including commercial and industrial loans, single payment personal loans, installment loans, and commercial and residential real estate loans.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: